Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2019 Elsevier Inc. except certain content provided by third parties. Privacy Policy   Terms and Conditions

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2019 Elsevier Inc. except certain content provided by third parties.
Privacy Policy   Terms and Conditions
Read More

CATEGORIES
TAGS
Share This

COMMENTS

Wordpress (0)
Disqus ( )